Hemogenyx Pharmaceuticals PLC (HEMO) — Financial Flexibility Index
Hemogenyx Pharmaceuticals PLC (HEMO) has a Financial Flexibility Index of -0.53x as of December 2024. Free cash flow of GBX-1.77 Million (operating CF GBX-1.78 Million minus capex GBX13.29K) represents -1% of total liabilities (GBX3.36 Million). Check Hemogenyx Pharmaceuticals PLC investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Hemogenyx Pharmaceuticals PLC Financial Flexibility Index (2015–2024)
Historical Financial Flexibility Index trend for Hemogenyx Pharmaceuticals PLC across 10 annual periods. For the full cash flow conversion analysis, see Hemogenyx Pharmaceuticals PLC (HEMO) cash flow conversion.
Annual Financial Flexibility Index for Hemogenyx Pharmaceuticals PLC (2015–2024)
Year-by-year free cash flow to debt coverage for Hemogenyx Pharmaceuticals PLC. Explore Hemogenyx Pharmaceuticals PLC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.22x | GBX-4.10 Million | GBX-4.12 Million | GBX3.36 Million | ▲ +32.1% |
| 2023 | -1.80x | GBX-5.99 Million | GBX-6.11 Million | GBX3.32 Million | ▼ -179.3% |
| 2022 | -0.64x | GBX-2.48 Million | GBX-2.91 Million | GBX3.85 Million | ▲ +87.4% |
| 2021 | -5.13x | GBX-1.81 Million | GBX-2.63 Million | GBX352.84K | ▼ -464.4% |
| 2020 | -0.91x | GBX-1.63 Million | GBX-1.80 Million | GBX1.79 Million | ▼ -7.0% |
| 2019 | -0.85x | GBX-1.19 Million | GBX-1.20 Million | GBX1.40 Million | ▲ +14.3% |
| 2018 | -0.99x | GBX-1.33 Million | GBX-1.35 Million | GBX1.34 Million | ▲ +32.8% |
| 2017 | -1.47x | GBX-388.72K | GBX-452.98K | GBX263.69K | ▲ +23.8% |
| 2016 | -1.93x | GBX-277.96K | GBX-278.15K | GBX143.69K | ▼ -599099.8% |
| 2015 | 0.00x | GBX79.71 | GBX79.71 | GBX246.83K | — |